Quale sarebbe il prezzo per BioVaxys Technology Corp. (BIOV)

Il prezzo per BioVaxys Technology Corp. (BIOV) è $0.05137558

Qual è la capitalizzazione di mercato per BioVaxys Technology Corp. (BIOV)

La capitalizzazione di mercato per BioVaxys Technology Corp. (BIOV) è $1.50M

BioVaxys Technology Corp. (BIOV) Frazionamenti Azionari

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

Anno	Frazionamento	Moltiplicatore	Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.

Anno

Frazionamento

Moltiplicatore

Moltiplicatore cumulativo

Non abbastanza dati per le date fornite.

Azienda	Numero di frazionamenti azionari	Moltiplicatore cumulativo	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Azienda

Numero di frazionamenti azionari

Moltiplicatore cumulativo

Il paese